FLT3 and acute myeloid leukemia: FLT3 mutations are detected in about 30% of newly diagnosed AML cases patients (pts) and include either internal tandem duplications (ITDs, in approximately 25% of patients) or point mutations in the tyrosine kinase domain (TKD, 7–10% of patients) [8,9].